WiDr
Zellname |
Beschreibung |
Bestell-Nr. |
Einheit |
Preis, Euro |
|---|---|---|---|---|
WiDr |
Humane Kolon Adenokarzinom Zell-Linie |
300377 |
cryovial |
265,00 |
WiDr |
Humane Kolon Adenokarzinom Zell-Linie |
330377 |
vital |
335,00 |
| Designation: | WiDr |
| Depositor: | Noguchi |
| Organism: | Homo sapiens (human) |
| Age/Stage: | 78 years |
| Gender: | female |
| Tissue: | colon |
| Morphology: | epithelial |
| Celltype: | adenocarcinoma, colorectal |
| Growth Properties: | monolayer |
| Description: | According to Chen TR, 1987, the WiDr cell line is a derivative of the HT-29 cell line. The cells are negative for Colon Antigen 3 expression, but positive for keratin by immunoperoxidase staining. The cells expressed p53 antigen (the p53 produced has a G -> A mutation resulting in Arg -> His at position 273). Growth of WiDr cells is inhibited by tumor necrosis factor alpha (TNF Inhibitors of dihydrofolate reductase are highly cytotoxic to WiDr cells). |
| Culture Medium: | DMEM:Ham's F12 medium (1:1 mixture) supplemented with 2 mM L-glutamine and 10% fetal bovine serum. |
| Subculturing: | Remove medium and rinse with 0.02% EDTA (versene) solution. Add fresh 0.025% trypsin/0.2% EDTA solution and incubate at 37°C until the cells detach. Add fresh medium, remove trypsin by centrifugation and dispense into new flasks. |
| Split Ratio: | A ratio of 1:10 to 1:20 is recommended |
| Fluid Renewal: | Twice per week |
| Freeze Medium: | CM-1 (CLS Cell Lines Service) |
| Sterility: | Tests for mycoplasma, bacteria and fungi were negative |
| Biosafety Level: | 1 |
| Tumorigenic: | yes, in nude mice |
| DNA Profile (STR): | Amelogenin: X,X CSF1PO: 11,12 D13S317: 11,11 D16S539: 11,12 D5S818: 11,12 D7S820: 10 THO1: 6,6 TPOX: 8,9 vWA: 17,19 D3S1358: 15,17 D21S11: 29,30 D18S51: 13 Penta E: 14,16 Penta D: 11,13 D8S1179: 10 FGA: 20,22 CLS ∙ Cell Lines Service, 2010. |
| Antigen Expression: | HLA A24, A32, B15, B18 |
| Receptors Expressed: | epidermal growth factor (EGF) |
| Isoenzymes: | PGM1, 1-2; PGM3, 1-2; G6PD, B; ES-D, 1; PEP-D, 1; 6PGD, A |
| Reverse Transcriptase: | negative |
| Products: | carcinoembryonic antigen (CEA) 118 ng/106 cells/10 days; Colon Specific Antigen (CSAp); transforming growth factor beta; keratin |
References: Petricciani JC et al. A comparison of three in vivo assays for cell tumorigenicity. Cancer Res 34: 105-8, 1974. Noguchi PD et al. Chick embryonic skin as a rapid organ culture assay for cellular neoplasia. Science 199: 980-983, 1978. Tsuboi KK and Kwong LK. Antiproliferative agents and differential survival between normal and cancer cells. Cancer Res 38: 3745-50, 1978. Noguchi P et al. Characterization of WiDr: a human colon carcinoma cell line. In Vitro 15: 401-8, 1979. Petricciani JC et al. Characteristics of seven clones of the WiDr human colon adenocarcinoma cell line. In Vitro 18: 492-4, 1982. Sugarman BJ et al. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 230: 943-5, 1985. Chen TR et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet Cytogenet 27: 125-34,1987. Rodrigues NR et al. p53 mutations in colorectal cancer. Proc Natl Acad Sci USA 87: 7555-9, 1990. Smith SG et al. Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res 53: 5697-706, 1993. Olive PL and Banath JP. Multicell spheroid response to drugs predicted with the comet assay. Cancer Res 57: 5528-33, 1997. Tsao H et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res 58: 109-13, 1998. Ochiumi T et al. Neuropilin-1 is involved in regulation of apoptosis and migration of human colon cancer. INt J Oncol 29(1): 105-116, 2006. | |
